Highlights
- Hemostemix Inc.'s stock price surged by 25% amidst a spike in trading volume.
- The biotech firm is advancing in stem cell therapy, with its main product, ACP-01, in Phase II trials.
- Market activity positions Hemostemix with a market cap of C$32.67 million, highlighting investor interest.
Hemostemix Inc. (CVE:HEM) experienced a notable surge in its share price, climbing 25% during mid-day trading on a recent Friday. The trading volume also saw a substantial increase, amounting to 1,444,856 shares, a 111% jump compared to the average session volume. With these movements, the stock settled at C$0.35 after peaking at C$0.36, up from its previous close of C$0.28.
Hemostemix Stock Performance
The stock's performance has been remarkable, with its 50-day simple moving average set at C$0.13 and the 200-day average at C$0.09. Hemostemix now boasts a market capitalization of C$32.67 million, though it carries a price-to-earnings (PE) ratio of -18.75 and a beta of 0.20.
About Hemostemix
Hemostemix Inc., a clinical-stage biotechnology company, is dedicated to the development, manufacturing, and commercialization of blood-derived stem cell therapies. Based in Canada, the company's flagship product, ACP-01, is progressing through Phase II clinical trials aimed at treating vascular diseases, including cardiovascular and peripheral arterial diseases, angina pectoris, and ischemia.